Erythrocyte fatty acids as potential biomarkers in the diagnosis of advanced lung adenocarcinoma, lung squamous cell carcinoma, and small cell lung cancer

American Journal of Clinical Pathology

Volumn 142, Issue 1, 2014, Pages 111-120

  De Castro, Javier ^a   Rodríguez, Marina C ^a   Martínez Zorzano, Vicenta S ^b   Sánchez Rodríguez, Patricia ^c   Sánchez Yagüe, Jesus ^c  

^a Unidad de Mama Hospital de la Santísima Trinidad   (Spain)

^b UNIVERSITY OF VIGO   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Cytokeratins; Erythrocyte; Fatty acids; Lung adenocarcinoma; Lung squamous cell carcinoma; Non small cell lung cancer; Sialic acid; Small cell lung cancer; Tumor markers

Indexed keywords

ARACHIDONIC ACID; CHOLESTEROL; CYTOKERATIN; CYTOKERATIN 19 FRAGMENT; FATTY ACID; GLYCOCONJUGATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LINOLEIC ACID; PHOSPHATIDIC ACID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE; SIALIC ACID; SPHINGOMYELIN; STEARIC ACID; THIOBARBITURIC ACID; TRIACYLGLYCEROL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHMA; CANCER DIAGNOSIS; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ERYTHROCYTE; FATTY ACID ANALYSIS; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LIPID COMPOSITION; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL;

CYTOKERATINS; ERYTHROCYTE; FATTY ACIDS; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; NON-SMALL CELL LUNG CANCER; SIALIC ACID; SMALL CELL LUNG CANCER; TUMOR MARKERS;

ADENOCARCINOMA; AGED; CARCINOMA, SQUAMOUS CELL; ERYTHROCYTES; FATTY ACIDS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SMALL CELL LUNG CARCINOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84904558699     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP1QUQQLLT8BLI     Document Type: Article

References (52)

1. Monge-Corella M, García-Pérez J, Aragonés N, et al. Lung cancer mortality in towns near paper, pulp and board industries in Spain: a point source pollution study. BMC Public Health. 2008;8:288-298.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
3. Becker S, Kortza L, Helmschrodt C, et al. LC-MS-based metabolomics in the clinical laboratory. J. Chromatogr B. 2012;883-884:68-75.
4. Patterson AD, Maurhofer O, Beyoglu D, et al. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res. 2011;71:6590-6600.
5. Newcomer LM, King IB, Wicklund KG, et al. The association of fatty acids with prostate cancer risk. Prostate. 2001;47:262-268. (Pubitemid 32521745)
6. Pala V, Krogh V, Muti P, et al. Erythrocyte membrane fatty acids and subsequent breast cancer: a prospective Italian study. J Natl Cancer Inst. 2001;93:1088-1095. (Pubitemid 32717541)
7. Mikirova N, Riordan HD, Jackson JA, et al. Erythrocyte membrane fatty acid composition in cancer patients. P R Health Sci J. 2004;23:107-113.
8. Santos MT, Valles J, Marcus AJ, et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes: a new approach to platelet activation and recruitment. J Clin Invest. 1991;87:571-580.
9. Prisco D, Paniccia R, Coppo M, et al. Platelet activation and platelet lipid composition in pulmonary cancer. Prostaglandins Leukot Essent Fatty Acids. 1995;53:65-68.
10. Brittain JE, Mlinar KJ, Anderson CS, et al. Activation of sickle red blood cell adhesion via integrin-associated protein/CD47-induced signal transduction. J Clin Invest. 2001;107:1555-1562. (Pubitemid 32577083)
11. Hernández-Hernández A, Rodríguez MC, López-Revuelta A, et al. Alterations in erythrocyte membrane protein composition in advanced non-small cell lung cancer. Blood Cell Mol Dis. 2006;36:355-363. (Pubitemid 43776188)
12. de Castro J, Hernández-Hernández A, Rodríguez MC, et al. Comparison of changes in erythrocyte and platelet fatty acid composition and protein oxidation in advanced non-small cell lung cancer. Cancer Invest. 2006;24:339-345.
13. de Castro J, Hernández-Hernández A, Rodríguez MC, et al. Comparison of changes in erythrocyte and platelet phospholipid and fatty acid composition and protein oxidation in chronic obstructive pulmonary disease and asthma. Platelets. 2007;18:43-51.
14. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91:1616-1634. (Pubitemid 29479929)
15. Crawford JH, Chacko BK, Kevil CG, et al. The red blood cell and vascular function in health and disease. Antioxid. Redox Signal. 2004;6:992-999. (Pubitemid 39434935)
16. Altiay G, Ciftci A, Demir M, et al. High plasma D-dimer level is associated with decreased survival in patients with lung cancer. Clin Oncol. 2007;19:494-498. (Pubitemid 47181178)
17. de Castro J, Rodríguez MC, Martínez-Zorzano VS, et al. Erythrocyte and platelet phospholipid fatty acids as markers of advanced non-small cell lung cancer: comparison with serum levels of sialic acid, TPS and Cyfra 21-1. Cancer Invest. 2008;26:407-418. (Pubitemid 351601401)
18. de Castro J, Rodríguez MC, Martínez-Zorzano VS, et al. Platelet linoleic acid is a potential biomarker of advanced non-small cell lung cancer. Exp Mol Pathol. 2009;87:226-233.
19. Patel PS, Baxi BR, Balar DB. Significance of serum sialoglycoproteins in patients with lung cancer. Neoplasma. 1989;36:53-59. (Pubitemid 19079975)
20. Stringou E, Chondros K, Kouvaris J. Serum sialic acid (TSA/LSA) and carcinoembryonic antigen (CEA) levels in cancer patients undergoing radiotherapy. Anticancer Res. 1992;12:251-256.
21. Patel PS, Raval GN, Rawal RM. Comparison between serum levels of carcinoembryonic antigen, sialic acid and phosphohexose isomerase in lung cancer. Neoplasma. 1995;42:271-274.
22. Buccheri G, Ferrigno D. Cytokeratin-derived markers of lung cancer. Expert Rev Mol Diagn. 2001;1:315-322. (Pubitemid 34654436)
23. Calikoglu M, Unlu A, Tamer L, et al. The levels of serum vitamin C, malonyldialdehyde and erythrocyte reduced glutathione in chronic obstructive pulmonary disease and in healthy smokers. Clin Chem Lab Med. 2002;40:1028-1031. (Pubitemid 35356021)
24. Prisco D, Rogasi PG, Matucci M, et al. Increased thromboxane A2 generation and altered membrane fatty acid composition in platelets from patients with active angina pectoris. Thrombosis Res. 1986;44:101-112. (Pubitemid 16006899)
25. Prisco D, Rogasi PG, Paniccia R, et al. Altered membrane fatty acid composition and increased thromboxane A2 generation in platelets from patients with diabetes. Prostaglandins Leukot Essent Fatty Acids. 1989;35:15-23. (Pubitemid 19045746)
26. Kaplan KL, Owen J. Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood. 1981;57:199-202. (Pubitemid 11174877)
27. Aminoff D. Methods for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoids. Biochem J. 1961;81:384-392.
28. Warren L. The thiobarbituric acid assay of sialic acids. J Biol Chem. 1959;234:1971-1975.
29. Gornall AG, Bardawill CJ, David MM. Determination of serum proteins by means of Biuret reaction. J Biol Chem. 1949;177:751-766.
30. López-Revuelta A, Sánchez-Gallego JI, Hernández- Hernández A, et al. Increase in vulnerability to oxidative damage in cholesterol-modified erythrocytes exposed to t-BuOOH. Biochim Biophys Acta. 2005;1734:74-85.
31. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43-46. (Pubitemid 20255621)
32. Perneger TV. What's wrong with Bonferroni adjustments. Br Med J. 1998;316:1236-1238. (Pubitemid 28171344)
33. Park SH, God JM, Jo CH. Receiver operating characteristic (ROC) curve: practical review for radiologists. Korean J Radiol. 2004;5:11-18. (Pubitemid 38569451)
34. Burgueño MJ, García-Bastos JL, González-Biutrago JL. Las curvas ROC en la evaluación de las pruebas diagnósticas. Med Clin (Barc). 1995;104:661-670.
35. Erceq-Hurn DM, Mirosevich VM. Modern robust statistical methods: an easy way to maximize the accuracy and power of your research. Am Psychol. 2008,63:591-601.
36. DeBerardinis J, Thompson CB. Cellular metabolism and disease: what do metabolic outliers teach us? Cell. 2012;148:1132-1144.
37. Xu J, Chen Y, Zhang R, et al. Global and targeted metabolomics of esophageal squamous cell carcinoma discovers potential diagnostic and therapeutic biomarkers. Mol Cell Proteomics. 2013;2:1306-1318.
38. Wen T, Gao L, Wen Z, et al. Exploratory investigation of plasma metabolomics in human lung adenocarcinoma. Mol Biosyst. 2013;9:2370-2378.
39. Straface E, Rivabene R, Masella R, et al. Structural changes of the erythrocyte as a marker of non-insulin-dependent diabetes: protective effects of N-acetylcysteine. Biochem Biophys Res Commun. 2002;290:1393-1398. (Pubitemid 34687412)
40. Bordin L, Donà G, Sabbadin C, et al. Human red blood cells alterations in primary aldosteronism. J Clin Endocrinol Metab. 2013;98:2494-2501.
41. Váli L, Hahn O, Kupcsulik P, et al. Oxidative stress with altered element content and decreased ATP level of erythrocytes in hepatocellular carcinoma and colorectal liver metastases. Eur J Gastroenterol Hepatol. 2008;20:393-398. (Pubitemid 351533875)
42. Harris RB, Foote JA, Hakim IA, et al. Fatty acid composition of red blood cell membranes and risk of squamous cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev. 2005;14:906-912. (Pubitemid 40478555)
43. Khyshiktuev BS, Khyshiktueva NA, Ivanov VN, et al. Fatty acid composition of blood plasma lipids and erythrocytes in lung cancer patients [in Russian]. Vopr Med Khim. 1994;40:48-50.
44. Minetti M, Leto TL, Malorni W. Radical generation and alterations of erythrocyte integrity as bioindicators of diagnostic or prognostic value in COPD? Antioxid Redox Signal. 2008;10:829-836. (Pubitemid 351225894)
45. Das UN. Essential fatty acids: biochemistry, physiology and pathology. Biotechnol J. 2006;1:420-439.
46. Pidgeon GP, Lysaght J, Krishnamoorthy S, et al. Lipoxigenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev. 2007;26:503-524. (Pubitemid 350115127)
47. Sakai M, Kakutani S, Horikawa C, et al. Arachidonic acid and cancer risk: a systematic review of observational studies. BMC Cancer. 2012;12:606.
48. Pujol JL, Grenier J, Parrat E, et al. Cytokeratins as serum markers in lung cancer: a comparison of Cyfra 21-1 and TPS. Am J Respir Crit Care Med. 1996;154:725-733. (Pubitemid 26327298)
49. Okamura K, Takayama K, Izumi M, et al. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer. Lung Cancer. 2013;80:45-49.
50. Alatas F, Alatas O, Metintas M, et al. Diagnostic value of CEA, CA 15-3, CA 19-9, Cygra 21-1, NSE and TSA assay in pleural effusions. Lung Cancer. 2001;31:9-16. (Pubitemid 32012598)
51. Narayanan S. Sialic acid as a tumor marker. Ann Clin Lab Sci. 1994;24:376-384. (Pubitemid 24203481)
52. Feijoo-Carnero C, Rodríguez-Berrocal FJ, Páez de la Cadena M, et al. Clinical significance of preoperative serum sialic acid levels in colorectal cancer: utility in the detection of patients at high risk of tumor recurrence. Int J Biol Markers. 2004;19:38-45. (Pubitemid 38515010)